TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT)

BMC Cardiovascular Disorders

Study Protocol

Helen M Pattison¹  Christian Borg Xuereb²  Gregory YH Lip²  Danielle E Smith²  Deirdre A Lane² 

[1] School of Health and Life Sciences, Aston University, Aston Triangle, B4 7ET, Birmingham, UK;University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Dudley Road, B18 7QH, Birmingham, UK;School of Health and Life Sciences, Aston University, Aston Triangle, B4 7ET, Birmingham, UK;

关键词: Atrial Fibrillation;    Warfarin;    Usual Care;    International Normalise Ratio;    Atrial Fibrillation Patient;   

DOI  :  10.1186/1471-2261-10-21

 received in 2009-12-14, accepted in 2010-05-20,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundAtrial fibrillation (AF) patients with a high risk of stroke are recommended anticoagulation with warfarin. However, the benefit of warfarin is dependent upon time spent within the target therapeutic range (TTR) of their international normalised ratio (INR) (2.0 to 3.0). AF patients possess limited knowledge of their disease and warfarin treatment and this can impact on INR control. Education can improve patients' understanding of warfarin therapy and factors which affect INR control.Methods/DesignRandomised controlled trial of an intensive educational intervention will consist of group sessions (between 2-8 patients) containing standardised information about the risks and benefits associated with OAC therapy, lifestyle interactions and the importance of monitoring and control of their International Normalised Ratio (INR). Information will be presented within an 'expert-patient' focussed DVD, revised educational booklet and patient worksheets. 200 warfarin-naïve patients who are eligible for warfarin will be randomised to either the intervention or usual care groups. All patients must have ECG-documented AF and be eligible for warfarin (according to the NICE AF guidelines). Exclusion criteria include: aged < 18 years old, contraindication(s) to warfarin, history of warfarin USE, valvular heart disease, cognitive impairment, are unable to speak/read English and disease likely to cause death within 12 months. Primary endpoint is time spent in TTR. Secondary endpoints include measures of quality of life (AF-QoL-18), anxiety and depression (HADS), knowledge of AF and anticoagulation, beliefs about medication (BMQ) and illness representations (IPQ-R). Clinical outcomes, including bleeding, stroke and interruption to anticoagulation will be recorded. All outcome measures will be assessed at baseline and 1, 2, 6 and 12 months post-intervention.DiscussionMore data is needed on the clinical benefit of educational intervention with AF patients receiving warfarin.Trial registrationISRCTN93952605

【 授权许可】

Unknown   
© Smith et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.